KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Long-Term Investments: 2020-2024

Historic Long-Term Investments for AbCellera Biologics (ABCL) over the last 5 years, with Dec 2024 value amounting to $82.3 million.

  • AbCellera Biologics' Long-Term Investments rose 10.96% to $93.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.3 million, marking a year-over-year increase of 10.96%. This contributed to the annual value of $82.3 million for FY2024, which is 24.81% up from last year.
  • According to the latest figures from FY2024, AbCellera Biologics' Long-Term Investments is $82.3 million, which was up 24.81% from $65.9 million recorded in FY2023.
  • In the past 5 years, AbCellera Biologics' Long-Term Investments ranged from a high of $82.3 million in FY2024 and a low of $19.2 million during FY2020.
  • In the last 3 years, AbCellera Biologics' Long-Term Investments had a median value of $72.5 million in 2022 and averaged $73.6 million.
  • As far as peak fluctuations go, AbCellera Biologics' Long-Term Investments skyrocketed by 161.41% in 2021, and later fell by 9.08% in 2023.
  • AbCellera Biologics' Long-Term Investments (Yearly) stood at $19.2 million in 2020, then spiked by 161.41% to $50.3 million in 2021, then skyrocketed by 44.14% to $72.5 million in 2022, then decreased by 9.08% to $65.9 million in 2023, then rose by 24.81% to $82.3 million in 2024.